Viking Therapeutics, Inc. Operating Leases, Future Minimum Payments, Due in Five Years
Viking Therapeutics, Inc. (VKTX) had Operating Leases, Future Minimum Payments, Due in Five Years of $29.00 thousand as of 2018-09-30, per its 10-Q filed 2018-11-07.
Discontinued › Notes › Leases
us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears · last filed 2018-11-07
- 2018-09-30: Operating Leases, Future Minimum Payments, Due in Five Years $29.00K.
- 2018-06-30: Operating Leases, Future Minimum Payments, Due in Five Years $29.00K.
| Period end | Operating Leases, Future Minimum Payments, Due in Five Years |
|---|---|
| 2018-09-30 | $29.00K 10-Q · filed 2018-11-07 |
| 2018-06-30 | $29.00K 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |